Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

Carfilzomib公司 医学 临时的 中期分析 内科学 多发性骨髓瘤 来那度胺 耐火材料(行星科学) 肿瘤科 加药 临床试验 材料科学 复合材料 考古 历史
作者
Philippe Moreau,María‐Victoria Mateos,James R. Berenson,Katja Weisel,Antonio Lazzaro,Kevin Song,Meletios Α. Dimopoulos,Mei Huang,Anita Zahlten-Kümeli,A. Keith Stewart
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (7): 953-964 被引量:191
标识
DOI:10.1016/s1470-2045(18)30354-1
摘要

Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 70 mg/m2 in combination with dexamethasone. We aimed to compare progression-free survival in patients with relapsed and refractory multiple myeloma given once weekly carfilzomib or twice weekly carfilzomib.In this prespecified interim analysis of the randomised, open-label, phase 3 A.R.R.O.W. trial, we recruited patients (aged 18 years and older) with relapsed and refractory multiple myeloma previously treated with two or three treatments, including a proteasome inhibitor and immunomodulatory agent, from hospital, clinic, oncology or medical centres. Key eligibility criteria were refractory to most recent therapy (including bortezomib or ixazomib) with measurable disease, and Eastern Cooperative Oncology Group Performance Status of 0 or 1. Patients were randomly assigned (1:1) to receive carfilzomib once a week (70 mg/m2) or twice a week (27 mg/m2). The randomisation sequence was generated using a validated randomisation software and implemented using an interactive response technology system that assigned patients to treatment sequentially based on the randomisation sequence as patients were enrolled at participating clinical sites. Patients were stratified by International Staging System stage at study entry or baseline, whether or not they were refractory to bortezomib treatment, and age (block size of 4). The once weekly group received carfilzomib (30 min intravenous infusion) on days 1, 8, and 15 of all cycles (20 mg/m2 day 1 [cycle 1]; 70 mg/m2 thereafter). The twice weekly group received carfilzomib (10 min intravenous infusion) on days 1, 2, 8, 9, 15, and 16 (20 mg/m2 days 1 and 2 during cycle 1; 27 mg/m2 thereafter). All patients received dexamethasone (40 mg on days 1, 8, 15 [all cycles] and 22 [cycles 1-9 only]). Treatment continued until disease progression or unacceptable toxic effects. The primary objective was to compare progression-free survival between groups in the intention-to-treat population. Safety analysis was done in all randomly assigned patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02412878, and is no longer enrolling patients.Between September, 2015, and August, 2016, 578 patients were recruited from 118 sites. 478 patients were randomly assigned and included in the efficacy analyses (240 to receive once weekly carfilzomib; 238 to receive twice weekly carfilzomib). Median progression-free survival was higher in the once weekly group than the twice weekly group (11·2 months [95% CI 8·6-13·0] vs 7·6 months [5·8-9·2]; hazard ratio [HR] 0·69, 95% CI 0·54-0·83; p=0·0029). The incidence of grade 3 or worse adverse events was higher in the once weekly group than the twice weekly group (68% [n=161] vs 62% [n=145]); the most common events were anaemia, pneumonia, and thrombocytopenia (42 [18%] vs 42 [18%], 24 [10%] vs 16 [7%], and 17 [7%] vs 16 [7%], respectively for once weekly carfilzomib vs twice weekly carfilzomib). A lower proportion of patients had grade 3 or worse cardiac failure in the once weekly group (7 [3%]) than in the twice weekly group (10 [4%]). Treatment-related deaths occurred in five (2%) of 238 patients in the once weekly group (sepsis [n=1], death [n=1], acute lung injury [n=1], acute respiratory distress syndrome [n=1], and tumour lysis syndrome [n=1]) and in two (1%) of 235 patients in the twice weekly group (plasma cell myeloma [n=1] and congestive heart failure [n=1]). There were 58 deaths in the once weekly group and 68 deaths in the twice weekly group at the time of data cutoff.Once weekly carfilzomib at 70 mg/m2 significantly prolonged progression-free survival versus the twice weekly schedule. Overall safety was comparable between the groups. Once weekly carfilzomib appears safe and more effective with a convenient dosing regimen versus the twice weekly schedule for the treatment of patients with relapsed and refractory multiple myeloma.Amgen, Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaobai发布了新的文献求助10
2秒前
zrj完成签到,获得积分10
2秒前
打打应助儒雅寻菱采纳,获得10
2秒前
思源应助lily采纳,获得10
3秒前
赵梅子完成签到,获得积分10
3秒前
4秒前
5秒前
11111完成签到,获得积分10
5秒前
小王发布了新的文献求助10
5秒前
6秒前
北城发布了新的文献求助10
6秒前
谷雨完成签到 ,获得积分10
7秒前
7秒前
大个应助科研通管家采纳,获得30
7秒前
乐乐应助欣慰的血茗采纳,获得10
7秒前
小蘑菇应助科研通管家采纳,获得10
7秒前
7秒前
Akim应助科研通管家采纳,获得10
8秒前
8秒前
yx_cheng应助科研通管家采纳,获得10
8秒前
8秒前
8秒前
烟花应助科研通管家采纳,获得10
8秒前
8秒前
科研通AI2S应助科研通管家采纳,获得10
8秒前
今后应助科研通管家采纳,获得20
8秒前
武雨寒发布了新的文献求助10
9秒前
9秒前
10秒前
liang完成签到,获得积分10
10秒前
11111发布了新的文献求助10
11秒前
华仔应助暴走农民采纳,获得10
13秒前
大力水香发布了新的文献求助10
13秒前
13秒前
dagongren完成签到,获得积分10
14秒前
yiw完成签到,获得积分10
15秒前
小梦发布了新的文献求助10
16秒前
16秒前
强哥完成签到,获得积分10
18秒前
19秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975900
求助须知:如何正确求助?哪些是违规求助? 3520207
关于积分的说明 11201602
捐赠科研通 3256663
什么是DOI,文献DOI怎么找? 1798403
邀请新用户注册赠送积分活动 877564
科研通“疑难数据库(出版商)”最低求助积分说明 806430